ERBB2 and breast carcinoma: In addition, in HER2- or ERBB2-enriched breast cancer, dimerization with HER3/ERBB3 elicits robust activation of PI3K and Akt, since HER3/ERBB3 possesses six docking sites for PI3K (Figure 1).